Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.
Olof Zachrisson, Malin Johannesson, Linda Söderberg, Fredrik Eriksson, Dan Sunnemark, Eva Nordström, My Björklund, Emily B Button, Tomas Odergren, Christer Möller, Gunilla Osswald, Johanna Fälting
Published: 202510.1016/j.neurot.2025.e00779
Abstract
Abnormal accumulation of α-synuclein in neuronal and/or glial cells occurs in a range of neurodegenerative conditions, including Parkinson's disease, Parkinson's disease dementia, dementia with Lewy bodies, and multiple system atrophy. Immunotherapy…
Preview only. Read the full abstract at the source